Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb dose-ranging study of GSK3640254 versus dolutegravir in treatment-naive adults with HIV-1 infection
2019-004435-23Phase 2Completed
- Sponsor
- ViiV Healthcare
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in Human immunodeficiency virus infection type 1 comparing GSK3640254 plus 2 NRTIs with Dolutegravir reference arm plus 2 NRTIs (2 arms). Primary endpoint: Proportion of participants with plasma HIV-1 RNA <50 copies/mL at Week 24. Started Jul 2020; status: completed.
02
Drugs
fipravirimatdolutegravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2019-004435-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004435-23.